Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENHANCE-IT: MAT9001 vs Vascepa in Hypertriglyceridemia
NCT04177680Phase 2Completed
- Sponsor
- Matinas BioPharma
- Start
- Jun 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MAT9001 in hypertriglyceridemia (2 arms), sponsored by Matinas BioPharma. Primary endpoint: Percent Change in Plasma Triglycerides at 28 days. Started Jun 2020; status: completed.
02
Drugs
MAT9001
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT04177680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04177680.